Conversion to sirolimus in renal transplant recipients with skin cancer

Transplantation

Volumn 82, Issue 12, 2006, Pages 1792-1793

  Tessmer, Chiara Scaglioni ^a   Da Silva Magalhães, Luiza Vieira ^a   Keitel, Elizete ^b   Valar, Cristiana ^b   Gnatta, Diego ^b   Pra, Ronivan Luis Dal ^b   Silveira, Fabiano Roldão ^b   Dos Santos, Auri Ferreira ^b   Goldani, João Carlos ^b   Garcia, Valter Duro ^b,d   Garcia, Clotilde Druck ^c  

^a FEDERAL UNIVERSITY OF PELOTAS   (Brazil)

^b Renal and Pancreas Transplant Unit   (Brazil)

^c Department of Pharmacology   (Brazil)

^d Complexo Hospitalar Santa Casa ^*  (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADULT; BASAL CELL CARCINOMA; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HISTOLOGY; HUMAN; HUMAN TISSUE; KAPOSI SARCOMA; KIDNEY CARCINOMA; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LETTER; MALE; MELANOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SKIN CANCER; SQUAMOUS CELL CARCINOMA; STATISTICAL ANALYSIS; TREATMENT DURATION;

AGED; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; SIROLIMUS; SKIN NEOPLASMS;

EID: 33845921185     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000250767.67472.58     Document Type: Letter

References (13)

1. Chapman J, Webter A. Cancer Report, ANZDATA (Australian and New Zealand Dialysis and Transplant Registry) Registry 2004 Report, Adelaide, South Australia, 2005. Available from: http://www.unzdata.org.au. Accessed September 30, 2006.
2. Hiesse C, Rieu P, Kriaa F, et al. Malignancy after renal transplantation: analysis of incidence and risk factors in 1700 patients followed during a 25-year period. Transplant Proc 1997; 29: 831.
3. Kasiske BL, Snyder JJ, Gilbertson DT, et al. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905.
4. Euvrard S, Kanitakis J, Claudy A. Skin cancers in organ transplantation. N Engl J Med 2003; 348: 1681.
5. Stockfleth E, Ulrich C, Meyer T, Christophers E. Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment. Recent Results Cancer Res 2002; 160: 251.
6. Otley CC, Coldiron BM, Stasko T, Goldman GD. Decreased skin cancer after cessation of therapy with transplant-associated immunosuppressants. Arch Dermatol 2001; 137: 459.
7. Guba M, Von Breitenbuch P, Steinbauer M, et al. SRL inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128.
8. Mathew T, Kreis H, Doyen K. Malignancy in renal transplant recipients receiving sirolimus (Rapamune) maintenance therapy: 2-year follow-up from 5 multicenter studies [abstract]. Transplantation 2002; 74(Suppl): 131.
9. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibiotrs is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80: 883.
10. Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol; 2006; 17: 581.
11. Stallone G. Sirolimus for Kaposi's sarcoma in renal transplant recipients. N Engl J Med 2005; 352: 1317.
12. Yakupoglu Y, Kahan B. Low incidence of malignancy among renal transplant recipients treated with a sirolimus-CsA regimen [abstract]. Am J Transplant 2003; 3(Suppl 5): 186.
13. Euvrard S, Kanitakis J, Decullier E, et al. Subsequente skin cancers in kidneys and heart transplant recipients after the first squamous cell carcinoma. Transplantation 2006; 81: 1093.